Use Of Melanocortin 4 Receptor Agonist In Preventing Or Treating Rare

Use Of Melanocortin 4 Receptor Agonist In Preventing Or Treating Rare Genetic Obesity Disease

Abstract: The present invention relates to a use of a compound of chemical formula 1 or a pharmaceutically acceptable salt thereof for preventing or treating rare genetic obesity diseases associated with a damaged melanocortin-4 receptor (MC4R) pathway, particularly rare genetic obesity diseases associated with proopiomelanocortin (POMC) deficiency.

Patent Information

Application #

Filing Date

07 September 2024

Publication Number

52/2024

Publication Type

INA

Invention Field

CHEMICAL

Status

Email

Parent Application

Applicants

LG CHEM, LTD.

128, Yeoui-daero Yeongdeungpo-gu Seoul 07336

Inventors

1. PARK, Hee Dong

E8 Block LG Science Park, 30, Magokjungang 10-ro Gangseo-gu Seoul 07796

2. HWANG, Hye Kyeong

E8 Block LG Science Park, 30, Magokjungang 10-ro Gangseo-gu Seoul 07796

3. YEO, Su Jin

E8 Block LG Science Park, 30, Magokjungang 10-ro Gangseo-gu Seoul 07796

Specification

Documents

Application Documents

#	Name	Date
1	202417067731-STATEMENT OF UNDERTAKING (FORM 3) [07-09-2024(online)].pdf	2024-09-07
2	202417067731-REQUEST FOR EXAMINATION (FORM-18) [07-09-2024(online)].pdf	2024-09-07
3	202417067731-POWER OF AUTHORITY [07-09-2024(online)].pdf	2024-09-07
4	202417067731-FORM 18 [07-09-2024(online)].pdf	2024-09-07
5	202417067731-FORM 1 [07-09-2024(online)].pdf	2024-09-07
6	202417067731-DRAWINGS [07-09-2024(online)].pdf	2024-09-07
7	202417067731-DECLARATION OF INVENTORSHIP (FORM 5) [07-09-2024(online)].pdf	2024-09-07
8	202417067731-COMPLETE SPECIFICATION [07-09-2024(online)].pdf	2024-09-07
9	202417067731-Verified English translation [13-09-2024(online)].pdf	2024-09-13
10	202417067731-FORM 3 [19-12-2024(online)].pdf	2024-12-19
11	202417067731-Verified English translation [13-02-2025(online)].pdf	2025-02-13
12	202417067731-Proof of Right [24-02-2025(online)].pdf	2025-02-24